ReviewInflammopharmacology2025
Exploring the role of inflammatory regulatory effects of probiotics as adjuvants in cancer development management with considering possible challenges: a comprehensive review.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- The Potential Anticancer Mechanisms of Probiotics: A Comprehensive Review.Probiotics and antimicrobial proteins · 2026Review
- Application and Challenges of Using ProbioticDiseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics have gained significant interest due to their versatile therapeutic and preventive potential. These beneficial microorganisms have primarily been studied in gastrointestinal disorders and, due to their inflammatory regulatory effects, have then been investigated for their effects on a wide range of conditions, from acute illnesses and chronic diseases to inflammation-related diseases, including cancer. Probiotics can not only restore microbiome balance following different treatments, from antibiotic therapy to some cancer treatments, but also, with their immunomodulatory and inflammatory regulation effects, they can induce potent immune responses in different conditions with minor side effects. Moreover, as they can secrete anti-inflammatory cytokines as well as reduce pro-inflammatory cytokines as well as chemokine, they can be applied to prevent the development of many inflammation disorders. Therefore, studies have been directed to survey probiotic adjuvant effects, especially regarding their potential in the reduction of inflammation to become chronic. Probiotics, as an adjuvant, can increase the antigens displayed to related cells and thus activate different immune response compartments. Moreover, probiotic adjuvant can modulate inflammation in cancer development, making them strong candidates for regulating inflammation. With the increase and improvement in our knowledge about the adjuvant role of probiotics in the inflammatory processes underlying cancer development, it is pivotal to review current studies in this field. Therefore, the current study strives to provide a review of the latest studies regarding the probiotic's adjuvant effect in the field of immunology and oncology research to benefit the scientific community.
Indexed as
Identifiers
40670830What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.